Bromocholine bromide (BETAB) is primarily used in biochemical and pharmacological research as a choline kinase inhibitor. It plays a significant role in studying cellular processes, particularly in cancer research, where it helps investigate the metabolism of choline and its impact on tumor growth. BETAB is also utilized in experiments exploring phospholipid metabolism, as it disrupts the synthesis of phosphatidylcholine, a key component of cell membranes. Additionally, it serves as a tool in neurobiology studies to understand cholinergic signaling pathways and their implications in neurological disorders. Its application extends to the development of therapeutic strategies targeting diseases associated with abnormal choline metabolism.